198 related articles for article (PubMed ID: 25435369)
1. The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V.
Agarwal S; Kazi JU; Mohlin S; Påhlman S; Rönnstrand L
Oncogene; 2015 Aug; 34(35):4581-90. PubMed ID: 25435369
[TBL] [Abstract][Full Text] [Related]
2. KIT-D816V oncogenic activity is controlled by the juxtamembrane docking site Y568-Y570.
Chaix A; Arcangeli ML; Lopez S; Voisset E; Yang Y; Vita M; Letard S; Audebert S; Finetti P; Birnbaum D; Bertucci F; Aurrand-Lions M; Dubreuil P; De Sepulveda P
Oncogene; 2014 Feb; 33(7):872-81. PubMed ID: 23416972
[TBL] [Abstract][Full Text] [Related]
3. The PI3-kinase isoform p110δ is essential for cell transformation induced by the D816V mutant of c-Kit in a lipid-kinase-independent manner.
Sun J; Mohlin S; Lundby A; Kazi JU; Hellman U; Påhlman S; Olsen JV; Rönnstrand L
Oncogene; 2014 Nov; 33(46):5360-9. PubMed ID: 24213578
[TBL] [Abstract][Full Text] [Related]
4. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
Pan J; Quintás-Cardama A; Kantarjian HM; Akin C; Manshouri T; Lamb P; Cortes JE; Tefferi A; Giles FJ; Verstovsek S
Blood; 2007 Jan; 109(1):315-22. PubMed ID: 16912224
[TBL] [Abstract][Full Text] [Related]
5. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant.
Chian R; Young S; Danilkovitch-Miagkova A; Rönnstrand L; Leonard E; Ferrao P; Ashman L; Linnekin D
Blood; 2001 Sep; 98(5):1365-73. PubMed ID: 11520784
[TBL] [Abstract][Full Text] [Related]
6. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
Pedersen M; Rönnstrand L; Sun J
Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
[TBL] [Abstract][Full Text] [Related]
7. PI3 kinase is indispensable for oncogenic transformation by the V560D mutant of c-Kit in a kinase-independent manner.
Lindblad O; Kazi JU; Rönnstrand L; Sun J
Cell Mol Life Sci; 2015 Nov; 72(22):4399-407. PubMed ID: 26040420
[TBL] [Abstract][Full Text] [Related]
8. D816V mutation in the KIT gene activation loop has greater cell-proliferative and anti-apoptotic ability than N822K mutation in core-binding factor acute myeloid leukemia.
Omori I; Yamaguchi H; Miyake K; Miyake N; Kitano T; Inokuchi K
Exp Hematol; 2017 Aug; 52():56-64.e4. PubMed ID: 28506695
[TBL] [Abstract][Full Text] [Related]
9. The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction.
Sun J; Pedersen M; Rönnstrand L
J Biol Chem; 2009 Apr; 284(17):11039-47. PubMed ID: 19265199
[TBL] [Abstract][Full Text] [Related]
10. Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation.
Jin Y; Ding K; Wang D; Shen M; Pan J
Cancer Lett; 2014 Oct; 353(1):115-23. PubMed ID: 25088577
[TBL] [Abstract][Full Text] [Related]
11. The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation.
Jin Y; Lu Z; Cao K; Zhu Y; Chen Q; Zhu F; Qian C; Pan J
Mol Cancer Ther; 2010 Jan; 9(1):211-23. PubMed ID: 20053766
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade.
Harir N; Boudot C; Friedbichler K; Sonneck K; Kondo R; Martin-Lannerée S; Kenner L; Kerenyi M; Yahiaoui S; Gouilleux-Gruart V; Gondry J; Bénit L; Dusanter-Fourt I; Lassoued K; Valent P; Moriggl R; Gouilleux F
Blood; 2008 Sep; 112(6):2463-73. PubMed ID: 18579792
[TBL] [Abstract][Full Text] [Related]
13. A change in structural integrity of c-Kit mutant D816V causes constitutive signaling.
Raghav PK; Singh AK; Gangenahalli G
Mutat Res; 2018 Mar; 808():28-38. PubMed ID: 29482074
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
[TBL] [Abstract][Full Text] [Related]
15. Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V.
Baumgartner C; Cerny-Reiterer S; Sonneck K; Mayerhofer M; Gleixner KV; Fritz R; Kerenyi M; Boudot C; Gouilleux F; Kornfeld JW; Sillaber C; Moriggl R; Valent P
Am J Pathol; 2009 Dec; 175(6):2416-29. PubMed ID: 19893034
[TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas9-engineering of HMC-1.2 cells renders a human mast cell line with a single D816V-KIT mutation: An improved preclinical model for research on mastocytosis.
Bandara G; Falduto GH; Luker A; Bai Y; Pfeiffer A; Lack J; Metcalfe DD; Olivera A
Front Immunol; 2023; 14():1078958. PubMed ID: 37025992
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit.
Corbin AS; Demehri S; Griswold IJ; Wang Y; Metcalf CA; Sundaramoorthi R; Shakespeare WC; Snodgrass J; Wardwell S; Dalgarno D; Iuliucci J; Sawyer TK; Heinrich MC; Druker BJ; Deininger MW
Blood; 2005 Jul; 106(1):227-34. PubMed ID: 15746079
[TBL] [Abstract][Full Text] [Related]
18. SRC-like adaptor protein 2 (SLAP2) is a negative regulator of KIT-D816V-mediated oncogenic transformation.
Rupar K; Moharram SA; Kazi JU; Rönnstrand L
Sci Rep; 2018 Apr; 8(1):6405. PubMed ID: 29686302
[TBL] [Abstract][Full Text] [Related]
19. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
Gleixner KV; Mayerhofer M; Sonneck K; Gruze A; Samorapoompichit P; Baumgartner C; Lee FY; Aichberger KJ; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P
Haematologica; 2007 Nov; 92(11):1451-9. PubMed ID: 18024392
[TBL] [Abstract][Full Text] [Related]
20. KIT
Phung B; Kazi JU; Lundby A; Bergsteinsdottir K; Sun J; Goding CR; Jönsson G; Olsen JV; Steingrímsson E; Rönnstrand L
Mol Cancer Res; 2017 Sep; 15(9):1265-1274. PubMed ID: 28584020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
